What is a stock summary page? Click here for an overview.
Business Description
Biosyent Inc
NAICS : 325412
SIC : 3741
ISIN : CA0906901081
Description
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.36 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.1 | |||||
| Interest Coverage | 151.08 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 14.98 | |||||
| Beneish M-Score | -1.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.8 | |||||
| 3-Year EBITDA Growth Rate | 10.1 | |||||
| 3-Year EPS without NRI Growth Rate | 9.5 | |||||
| 3-Year FCF Growth Rate | -0.2 | |||||
| 3-Year Book Growth Rate | 7.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.95 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.24 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.19 | |||||
| 9-Day RSI | 65.62 | |||||
| 14-Day RSI | 60.06 | |||||
| 3-1 Month Momentum % | -3.47 | |||||
| 6-1 Month Momentum % | -5.09 | |||||
| 12-1 Month Momentum % | 21.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.53 | |||||
| Quick Ratio | 3.54 | |||||
| Cash Ratio | 2.95 | |||||
| Days Inventory | 291.26 | |||||
| Days Sales Outstanding | 33.44 | |||||
| Days Payable | 237.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.68 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| Forward Dividend Yield % | 1.77 | |||||
| 5-Year Yield-on-Cost % | 1.68 | |||||
| 3-Year Average Share Buyback Ratio | 3.5 | |||||
| Shareholder Yield % | 5.92 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.52 | |||||
| Operating Margin % | 25.88 | |||||
| Net Margin % | 20.75 | |||||
| FCF Margin % | 11.26 | |||||
| ROE % | 20.53 | |||||
| ROA % | 17.32 | |||||
| ROIC % | 39.61 | |||||
| 3-Year ROIIC % | 3.51 | |||||
| ROC (Joel Greenblatt) % | 179.95 | |||||
| ROCE % | 26.94 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.55 | |||||
| Forward PE Ratio | 13.92 | |||||
| PE Ratio without NRI | 17.09 | |||||
| Shiller PE Ratio | 25.42 | |||||
| Price-to-Owner-Earnings | 17.01 | |||||
| PEG Ratio | 1.09 | |||||
| PS Ratio | 3.78 | |||||
| PB Ratio | 3.67 | |||||
| Price-to-Tangible-Book | 4.26 | |||||
| Price-to-Free-Cash-Flow | 32.58 | |||||
| Price-to-Operating-Cash-Flow | 15.26 | |||||
| EV-to-EBIT | 10.71 | |||||
| EV-to-EBITDA | 10.11 | |||||
| EV-to-Revenue | 3.01 | |||||
| EV-to-Forward-Revenue | 2.67 | |||||
| EV-to-FCF | 27.71 | |||||
| Price-to-GF-Value | 1.05 | |||||
| Price-to-Projected-FCF | 1.26 | |||||
| Price-to-DCF (Earnings Based) | 1.01 | |||||
| Price-to-DCF (FCF Based) | 2.21 | |||||
| Price-to-Median-PS-Value | 0.87 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.29 | |||||
| Price-to-Graham-Number | 1.84 | |||||
| Price-to-Net-Current-Asset-Value | 7.04 | |||||
| Price-to-Net-Cash | 13.36 | |||||
| Earnings Yield (Greenblatt) % | 9.34 | |||||
| FCF Yield % | 3.24 | |||||
| Forward Rate of Return (Yacktman) % | 17.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIOYF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Biosyent Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 25.47 | ||
| EPS (TTM) ($) | 0.449 | ||
| Beta | 0.44 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 15.89 | ||
| 14-Day RSI | 60.06 | ||
| 14-Day ATR ($) | 0.083894 | ||
| 20-Day SMA ($) | 7.6877 | ||
| 12-1 Month Momentum % | 21.04 | ||
| 52-Week Range ($) | 5.93 - 8.9 | ||
| Shares Outstanding (Mil) | 11.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosyent Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosyent Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biosyent Inc Frequently Asked Questions
What is Biosyent Inc(BIOYF)'s stock price today?
The current price of BIOYF is $7.88. The 52 week high of BIOYF is $8.90 and 52 week low is $5.93.
When is next earnings date of Biosyent Inc(BIOYF)?
The next earnings date of Biosyent Inc(BIOYF) is 2025-05-16 Est..
Does Biosyent Inc(BIOYF) pay dividends? If so, how much?
The Dividend Yield % of Biosyent Inc(BIOYF) is 1.68% (As of Today), Highest Dividend Payout Ratio of Biosyent Inc(BIOYF) was 0.3. The lowest was 0.09. And the median was 0.28. The Forward Dividend Yield % of Biosyent Inc(BIOYF) is 1.77%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers